• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day

    9/23/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    McKesson Corporation (NYSE:MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook.

    The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value creation:

    • Executing strategic priorities: Demonstrating significant progress, focusing on people and culture, strengthening North American Pharmaceutical distribution, modernizing and accelerating the portfolio, and expanding oncology, multispecialty, and biopharma services platforms.
    • Advancing portfolio optimization: Providing an update on portfolio developments, including the Medical-Surgical separation.
    • Reaffirming growth pillars: Highlighting McKesson's differentiated assets and capabilities across oncology, multispecialty, and biopharma services, positioning the company to lead in high-growth markets and improve patient health outcomes.
    • Introducing a new organizational structure: As announced on September 18, 2025, the new structure reflects McKesson's sharpened focus on accelerating growth, enhancing transparency, capital allocation and shareholder value creation.
    • Delivering financial updates: Providing a financial overview, updated Fiscal 2026 guidance and a long-term outlook that underscores the company's commitment to shareholder value creation.
    • Raising guidance: Increasing and narrowing Fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.05 to $38.55 from the previous range of $37.10 to $37.90.

    "Our strong track record and sustained success, built on operational excellence and disciplined execution, positions us well to advance our strategy and deliver meaningful impact across the healthcare ecosystem," said Brian Tyler, chief executive officer. "As we continue to strengthen our position and accelerate our strategic priorities, we remain focused on driving sustainable growth and creating long-term value for our shareholders."

    Fiscal 2026 Outlook

    McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

    McKesson is raising and narrowing fiscal 2026 Adjusted Earnings per Diluted Share guidance to $38.05 to $38.55 from the previous range of $37.10 to $37.90.

    Long-Term Growth Targets

    McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes for all. The company remains well-positioned to capture long-term growth opportunities through disciplined execution of its strategic priorities and sustained operational momentum.

    McKesson is updating its long-term growth targets and introducing segment-specific targets for the new reporting structure. McKesson is also updating and increasing its long-term Adjusted Earnings per Diluted Share growth target to 13% to 16%, an increase from the prior range of 12% to 14%. This reflects the strength of McKesson's leading platforms in oncology, multispecialty, and biopharma solutions, supported by operating leverage and efficient capital deployment.

    Following the announcement of the updated organizational structure, McKesson is initiating long-term Adjusted Segment Operating Profit growth targets for its newly defined segments, as follows:

     

    Long-Term Segment Growth Targets

    North American Pharmaceutical

    5% to 8%

    Oncology & Multispecialty

    13% to 16%

    Prescription Technology Solutions

    10% to 13%

    Additional modeling considerations will be provided in the Investor Day presentation.

    Webcast and Presentations

    The video webcast will be available live from 9:30 AM to 12:30 PM ET on Tuesday, September 23, 2025 at investor.mckesson.com/events-and-presentations. After the event, the archived video webcast will be available on McKesson's Investor Relations website, along with the company's slide presentation, at investor.mckesson.com.

    Upcoming Investor Events

    McKesson will release its second quarter fiscal 2026 financial results after market close on Wednesday, November 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM ET to review its financial results.

    McKesson management will be participating in the following investor events:

    • UBS Global Healthcare Conference, November 10, 2025
    • Evercore HealthCONx Conference, December 4, 2025
    • J.P. Morgan Healthcare Conference, January 12-15, 2026

    Cautionary Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimates," "targets," or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company and to sell our businesses in Norway, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.

    These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors; we may be adversely affected by global climate change or by regulatory or market responses to such change; and evolving expectations and regulatory requirements related to governance and sustainability matters, including those concerning human capital management, climate change, environmental responsibility, and social impact may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.

    About McKesson Corporation

    McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

    We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250922866263/en/

    Investors

    [email protected]

    Media Relations

    [email protected]

    Get the next $MCK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day

    McKesson Corporation (NYSE:MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook. The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value creation: Executing strategic priorities: Demonstrating significant progress, focusing on people and culture, strengthening North American Pharmaceutical distribution, modernizing and accelerating the portfolio, and expanding oncology, multispecialty, and biopharma services platforms. Advancing portfolio optimization: Provid

    9/23/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Announces New Organizational Structure

    Enhances Strategic Focus and Clarity to Capital Allocation McKesson Corporation (NYSE:MCK) today announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders. "McKesson has a long history of leadership in healthcare, continuously evolving to meet the needs of our customers, providers, and the patients we collectively serve," said Britt Vitalone, chief financial officer. "This updated reporting structure reflects a strategic evolution of our bu

    9/18/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv

    8/6/25 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    SEC Filings

    View All

    McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    9/23/25 8:03:51 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - MCKESSON CORP (0000927653) (Filer)

    9/18/25 8:00:41 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by McKesson Corporation

    10-Q - MCKESSON CORP (0000927653) (Filer)

    8/6/25 5:30:47 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tyler Brian S. sold $8,418,166 worth of shares (11,930 units at $705.63), decreasing direct ownership by 75% to 4,012 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/25/25 4:30:05 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Tyler Brian S. sold $8,085,677 worth of shares (11,930 units at $677.76), decreasing direct ownership by 43% to 15,942 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/19/25 10:20:40 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SVP, Controller & CAO Rutledge Napoleon B Jr sold $218,347 worth of shares (329 units at $663.67), decreasing direct ownership by 33% to 657 units (SEC Form 4)

    4 - MCKESSON CORP (0000927653) (Issuer)

    8/11/25 4:52:21 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho resumed coverage on McKesson with a new price target

    Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

    12/4/24 7:43:38 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

    11/7/24 6:29:13 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

    9/24/24 8:19:53 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    $MCK
    Financials

    Live finance-specific insights

    View All

    $MCK
    Leadership Updates

    Live Leadership Updates

    View All

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day

    McKesson Corporation (NYSE:MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company's multi-year strategic priorities, growth strategies, and long-term business outlook. The Investor Day event will showcase how McKesson continues to accelerate long-term growth and deliver sustained value creation: Executing strategic priorities: Demonstrating significant progress, focusing on people and culture, strengthening North American Pharmaceutical distribution, modernizing and accelerating the portfolio, and expanding oncology, multispecialty, and biopharma services platforms. Advancing portfolio optimization: Provid

    9/23/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance

    McKesson Corporation (NYSE:MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inv

    8/6/25 4:10:00 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Corporation Raises Quarterly Dividend by 15% to $0.82 Per Share

    The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal

    7/30/25 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

    10/4/23 4:05:00 PM ET
    $KRMD
    $MCK
    Medical/Dental Instruments
    Health Care
    Other Pharmaceuticals

    Gentherm Announces Dr. Ken Washington as New Independent Director

    NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

    10/2/23 8:00:00 AM ET
    $AMZN
    $F
    $MCK
    Catalog/Specialty Distribution
    Consumer Discretionary
    Auto Manufacturing
    Industrials

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/13/24 5:09:38 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    1/25/24 1:48:52 PM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

    SC 13G/A - MCKESSON CORP (0000927653) (Subject)

    2/10/22 8:27:59 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care